1212results about How to "Medication convenience" patented technology

The present invention discloses a slowly-released oral medicine preparation which is made up by using breviscapine as main raw material and has the functions of promoting blood circulation and removing blood stasis, removing obstruction in the channels to relieve pain for curing angiocardiopathy and cerebrovascular disease with obvious therapeutic effect and its preparation method. Said slowly-released tablet (by one tablet) contains 60-120 mg of breviscapine, 20-75 mg of diluent, 50-150 mg of filling agent and 10-50 mg of slow release material. Said invention also provides its preparation method and concrete steps.

The invention relates to a temperature sensitive gel formulation for in situ vagina uses which is prepared from effective dosage of medicament for treating female vagina infection and macromolecular findings through dissolving into cushioning solution or pure water, and charging poloxamer.

The invention discloses tilmicosin soluble powder, which consists of the following components in parts by weight: 1-50 parts of tilmicosin, 1-50 parts of a solid dispersoid carrier auxiliary material and 0-70 parts of a medical filling auxiliary material. The invention further discloses a preparation method of the tilmicosin soluble powder. The method comprises the following steps of: (1) adding the solid dispersoid carrier auxiliary material into a solubilizing assistant for dissolving; (2) adding tilmicosin, stirring and dissolving; and (3) drying. The tilmicosin soluble powder disclosed by the invention has the advantages of low water content, high solubility, high bioavailability and convenience for administration, and the palatability of animals can be improved simultaneously.

The invention provides an in situ eye gel preparation of penciclovir. The compositions and weight percentages thereof are 0.01-2.0wt% of penciclovir, 5-40wt% of poloxamer, 0.1-5wt% of tackifier high polymer base, 0.8-10wt% of osmotic regulation agent, 0.001-0.5wt% of antiseptics and the rest is distilled water. Meanwhile, the preparation method is also provided. The in situ gel preparation has good biocompatibility and glutinousness; compared with a liquid preparation, the invention can increase retention time of drug in the eyes and delay elimination, thus improving the bioavailability of the eyes and reducing the times of administration; meanwhile, the invention avoids weaknesses that operation is inconvenient during gel administration, the preparation is not easy to spread in eyes, the dosage can not be controlled accurately, etc.

The invention discloses a Chinese herbal microecological preparation for preventing and treating chicken Colibacillosis and a preparation method thereof. The Chinese herbal microecological preparation for preventing and treating chicken Colibacillosis is prepared by adding mixed bacterial liquid of bifidobacteria and bacillus subtilis with a total number of colonies of 0.5-1.0*10<8> CFU / ml into the extract of traditional Chinese medicines and carrying out hermetical anaerobic fermentation on an obtained mixture, wherein the traditional Chinese medicines comprise, by weight, 50 to 200 parts of coptis, 50 to 200 parts of phellodendron, 50 to 200 parts of rheum officinale, 50 to 200 parts of root of large-flowered skullcap, 50 to 200 parts of isatis root and 50 to 100 parts of licorice. The Chinese herbal microecological preparation for preventing and treating chicken Colibacillosis provided in the invention allows pharmaceutical activity of the compatible traditional Chinese medicines to be enhanced after fermentation treatment by using bacterial liquid of bifidobacteria and bacillus subtilis, reduces drug resistance exerted by the medicines on chicken on the basis of guaranteeing a good curative effect and maintains a good treatment effect after many times of administration.

The invention relates to an osmotic pump controlled release pharmaceutical composition which contains two medicine active ingredients and is used for treating hyperlipoidemia and a preparation method thereof, the pharmaceutical composition has a nicotinic acids medicine such as acipimox and the other one estatina medicine such as atorvastatin; wherein, the nicotinic acids medicine such as acipimox is a controlled release part, and the estatina medicine such as atorvastatin is a quick release part; or both the acipimox and the atorvastatin are the controlled release part. The compound osmotic pump preparation of the invention has the advantages of comprehensive action, low toxicity and side effects and convenient use.

The invention discloses an electronic prescription circulation method which comprises a step of receiving an electronic prescription sent by a hospital terminal, wherein the electronic prescription comprises medication information and basic information of a user, a step of carrying out reasonable medication examination on the medication information of the electronic prescription, a step of generating a corresponding drug taking pharmacy recommendation list according to the medication information when the medication information examination is approved, a step of sending the drug taking pharmacyrecommendation list to a corresponding user terminal according to the basic information of the user, a step of receiving drug taking pharmacy selection sent by the user terminal, and a step of pushing the electronic prescription to a corresponding pharmacy terminal according to the drug taking pharmacy selection. The invention also provides an electronic prescription circulation server and system, the electronization of a medical prescription is realized, the user can conveniently view the prescription in real time and carry and store the prescription, intelligent pharmacy recommendation is achieved, and the user can conveniently take medicines.

The invention provides a medical compound for treating osteoporosis which is characterized in that the invention contains strontium ranelate and bisphosphonate. Animal experiments indicate that the invention achieves the unexpected effect for treating the osteoporosis. The osteoporosis is a bone disease of the whole body characterized by the low bone mass and the degeneration of the micro structure of the bone organization, companying with the enhancement of the bone fragility and easy happened bone broken for which no ideal treatment medicine exists in the clinic. The bisphosphonate of the invention comprises alendronate, risedronate sodium, ibandronate, pamidronate, Etidronate, disodium clodronate and zoledronic acid, etc. In the invention, the dosage of the bisphosphonate is greatly reduced, which can effectively reduce the happening of side effects and is convenient to use the medicine.

The present invention relates to an earthworm acid region medicine for curing cough and asthma diseases and its preparation method. Said earthworm acid region medicine contains fatty acid, amino acid and purine compound, and can be used for curing the diseases of asthma and chronic bronchitis, etc. Its preparation method includes the following steps: using strong base anion-exchange resin to adsorb aqueous extract of earthworm, then using dilute hydrochloric acid or alcohol-containing dilute hydrochloric acid to make elution.

The invention belongs to the technical field of pharmaceutical preparation, in particular to a lansoprazole enteric-coated tablet; wherein, the enteric-coated tablet consists of the following components: a) tablet core consisting of lansoprazole and pharmaceutical excipient; b) a enteric coating layer consisting of castor oil, polyacrylic resin II and pharmaceutical excipient. The enteric coating layer of the invention contains castor oil which is water insoluble plasticizer and has good compatibility with the polyacrylic resin II, thereby effectively preventing the lansoprazole of the raw material from being damaged by the polyacrylic resin II which is the acidic and intestinal-lysis coating material; therefore, an isolated layer is not needed to be packed between an enteric-coated layer and a tablet core, and fatherly allowing the invention has the advantages of simplifying the preparation process, reducing production cost, high dissolution rate of the prepared enteric-coated tablet, high bioavailability and good stability.

The invention relates to an external composition, and a preparation and an application thereof and belongs to the field of medicines. The external composition provided by the invention is a medicine composition which contains chlorhexidine or officinal salt thereof, or benzalkonium bromide or officinal salt thereof and a recombinant human epidermal growth factor or a recombinant cattle alkali fibroblast growth factor. According to the invention, the medicine composition is also further prepared into gel, liniment, ointment or paste, and the gel further comprises chitosan or officinal salt thereof and hyaluronic acid or officinal salt thereof. When being used for treating vagina inflammation, the external composition disclosed by the invention can improve a vagina microenvironment, promote growth of granulation tissue and repair vagina micro damage; and when being used for skin wound atraumatic restorative treatment, the external composition also can speed up restoration and regeneration of a wound tissue, promote healing and reduce scar formation, so that the external composition has a wide medical application prospect.

The present invention discloses a kind of slow releasing enteric soluble coated tablet containing hyperzine A and its preparation process. Enteric soluble coating technology is adopted to overcome the bad effect of lower pH in stomach on the diffusion of medicine in skeleton tablet to ensure the stable, slow and complete release of medicine. The slow releasing tablet contains hyperzine A as reversible anticholinesterase and has one layer of enteric soluble polymer film coating outside the skeleton slow releasing layer. The active medicine component may be also various pharmaceutically acceptable acid salts of hyperzine A. Each tablet contains hyperzine A I n10-500 microgram and has sustained release time of 20 hr.

The invention relates to a medicine taking reminding medical kit which comprises a kit body, an identity recognition module, a processing module, a communication module, a prompt module and a control module. The kit body comprises a plurality of kit cells, and each kit cell correspondingly stores one kind of medicine and corresponds to one kit cell number; the identify recognition module is used for obtaining identity information of a medicine user; the control module transmits the identity information to a server through the communication module; the server pre-stores medicine use information corresponding to the identity information and feeds back the medicine use information corresponding to the identity information to the medicine kit; the processing module processes the medicine use information and generates prompt information; the control module controls the prompt module to broadcast the kit cell numbers and dosage corresponding to the kit cell numbers according to the prompt information.

The invention discloses a traditional Chinese medicine composition for treating allergic rhinitis, comprising the following crude medicines in parts by weight: 28-32 parts of honeysuckle, 28-32 parts of baical skullcap root, 28-32 parts of paniculate swallowwort root, 13-17 parts of xanthium, 13-17 parts of magnolia flower, 7-11 parts of asarum, 7-11 parts of mint, 13-17 parts of angelica, 13-17 parts of centipeda minima, 22-26 parts of chuanxiong rhizome and 16-20 parts of borneol. The preparation method comprises the steps of crushing all components, screening with a sieve of 200 meshes and mixing evenly. When used for treatment, the medicament provided by the invention is put into a medicine bag made of non-woven fabric, then the medicine bag is sown on the inner surface of a disposable mask, and a patient wears the mask and aligns the medicine bag with the nostrils. A course of treatment lasts for 5 days, and generally allergic rhinitis can be cured by two courses of treatment. The medicament provided by the invention is directly inhaled and has the advantages of quick effect taking, convenience in use, safety, reliability, no toxic side effect, low cost and the like.

The invention belongs to the technical field of medicine and relates to clopidogrel and salt submicron emulsion injection thereof as well as a preparation method of the clopidogrel and the salt submicron emulsion injection thereof. Particularly, the invention provides clopidogrel, salt submicron emulsion injection including clopidogrel, salt, oil for injection, assistant emulsifier, isoosmotic adjusting agents, pH adjusting agents and water for injection, and a preparation method of the clopidogrel and the salt submicron emulsion injection. 100 mL of the injection comprises clopidogrel, 0.05 g to 0.15 g salt (measured according to clopidogrel), 5 g to 30 g of oil for injection, 0.5 g to 3.4 g of emulsifier, 0 g to 1 g of assistant emulsifier, 2.0 g to 4.0 g of isoosmotic adjusting agents, and 7.0 g to 9.0 g of pH adjusting agents, and 100 mL of water for injection is added. The clopidogrel and the salt submicron emulsion injection thereof, provided by the invention, have the physical chemical property conforming to the requirement of drug for intravenous use and are suitable for clinical application.

The invention relates to an oral preparation containing andrographolide and a preparation method thereof, belonging to the field of medicines. The oral preparation containing andrographolide is in dosage forms of enteric-coated granules, enteric-coated tablets, enteric-coated capsules and enteric-coated dispersible tablets which are prepared by mixing andrographolide and pharmaceutically acceptable auxiliary materials. The prepared oral preparation can reduce incidence of adverse reactions and side effects thereof and improve the medication safety while ensuring the therapeutic effect, and uses the andrographolide more widely.

The invention relates to a method for preparing bilobalide tablet, which is characterized in that it is prepared from bilobalide drug as active component and relative findings, wherein, the bilobalide drug can be bilobalide or bilobalide B, and the findings contain hydrophilic gel which can quickly expand in the stomach acid condition and float in gastric; and the tablet has significant slow-release effect. The mass ration between the bilobalide drug and the findings is 1:0.3-30. The bilobalide drug is extracted from ginkgo leaf. And the preparation is characterized in that screening the bilobalide drug and findings via the screen at 80-100 deals to be mixed uniformly and pressed into tablet, or using wetting particle making technique or drying particle technique to press the tablet.

The present invention discloses one kind of interferon spray for lung administration and its preparation process. Liquid composition is first constituted with interferon in 0.0002-0.8 % and corresponding medicinal supplementary material, and then dried in proper process, such as spray drying process, to prepare efficient stable interferon spray. The present invention adopts active protecting agent to ensure no damage of the interferon activity during drying or serve as stabilizer. The interferon spray of the present invention contains no human serum albumin and absorption promoter and thus has no blood contamination and damage to lung.

The invention relates to a florenicol succinic acid monoester and a preparation method thereof, and the florenicol succinic acid monoester can be obtained by the esterification of the florenicol and succinic anhydride. Simultaneously, the invention also relates to acceptable salts and preparation methods thereof of the florenicol succinic acid monoester pharmacy, such as sodium salt, potassium salt, calcium salt and magnesium salt etc., and salts that are formed with basic amino acids and comprises lysine and arginine salts. By testing, the water-solubility of the corresponding salt is more than 500 mg / ml. The water-soluble derivatives disclosed by the invention quickly release the florenicol after being hydrolyzed in bodies and the derivatives can be used as high water-soluble prodrugs of the florenicol.

A Chinese medicine for treating burn, scald and cold injury is prepared from the oil of plant or animal, and 9 Chinese-medicinal materials including Chinese angelica root, arnebia root, sanguisorba root, myrrh, etc. Its preparing process is also disclosed.

The invention relates to a pharmaceutical composition of fulvestrant. The pharmaceutical composition comprises: (1) fulvestrant; (2) at least one pharmaceutically acceptable alcohol; (3) medium-chain triglyceride; and (4) a castor oil matrix.

The invention discloses a Chinese medicinal preparation for nourishing liver and kidney, supplementing qi, engendering blood, promoting blood circulation, removing meridian obstruction and relieving pain, which is prepared into capsules from the following Chinese medicinal herbs in weight proportion: 10 to 20 parts of prepared fleece-flower root, 10 to 20 parts of prepared rehmannia root, 10 to 15 parts of Chinese angelica, 10 to 15 parts of donkey-hide glue, 10 to 20 parts of white peony root, 5 to 10 parts of ginseng, 10 to 20 parts of pilose asiabell root, 10 to 20 parts of heterophylly falsestarwort root, 10 to 20 parts of astragalus root, 10 to 20 parts of large-head atractylodes rhizome, 10 to 20 parts of Chinese yam, 10 to 15 parts of frankincense, 10 to 15 parts of myrrh, 10 to 15 parts of corydalis tuber, and 10 to 15 parts of trogopterus dung. The prepared fleece-flower root for nourishing blood, boosting essence, promoting muscle growth and strengthening bones and the Chinese angelica for activating blood and dissolving stasis serve as monarch medicines; the prepared rehmannia root is good for tonifying yin and boosting essence to engender blood; the donkey-hide glue is good for enriching the blood; the white peony root is good for soothing the muscles and relieving pain; the ginseng is good for tonifying primordial qi; the pilose asiabell root and the heterophylly falsestarwort root are good for invigorating qi and strengthening spleen; the astragalus root and the large-head atractylodes rhizome are good for tonifying qi and engendering blood; the Chinese yam is good for strengthening spleen and kidney and controlling nocturnal emission; the corydalis tuber is good for activating blood, promoting qi circulation and relieving pain; the trogopterus dung is good for activating blood and dissolving stasis; the frankincense is good for promoting blood circulation and relaxing muscles and tendons; and the myrrh is good for eliminating swelling and easing pain.

A medicine in the form of injection, perfusion, tablet, capsule, or oral liquid for preventing and treating hypokalemia, early heartbeat and arrhythmia is prepared from levo-aminosuccinic acid (1-10 wt. portions), potassium salt (1-12) and auxiliary (0-100). Its advantages are sure curative effect, high stability and no pollution.

The vagina effervescent tablet has the salt or ester of clindamycin and metronidazole as active component and is prepared via a common tablet making process. The present invention features that the said effervescent tablet contains hydroxypropyl methyl cellulose as adhesive. Compared with conventional effervescent tablet, the present invention has the advantages of greater foam amount, fine and lasting foams, homogeneous distribution of effective medicine component, long duration, raised medicine curative effect, simple preparation process, stable quality and being suitable for industrial production.

A bisphosphonate for treatment of osteoporosis is formulated with an amount of an antifoaming agent effective for reducing foaming in the stomach, leading to reduced reflux and oesophageal irritation in use and increased patient compliance.

The invention discloses a Chinese traditional medicine for treating diabetes which comprises rhizoma dioscoreae, raw astragalus root, scrophularia root, gen-seng, lilyturf root, pulp of dogwood fruit, anemarrhena rhizome, prepared rhizome of rehmannia, schisandra fruit, root of Chinese trichosannthes, kudzu vine root, asparagus root, oriental water plantain rhizome and licorice root.

The invention relates to tilmicosin enteric-coated pellets. Each tilmicosin enteric-coated pellet is composed of a pellet core and a coating layer coating the pellet core. Each pellet core is composed of, by weight, 20-60% of tilmicosin, 5-35% of poloxamer 188 and 20-75% of microcrystalline cellulose. The size of the pellet cores is not larger than the mesh aperture of a 24-mesh sieve and not smaller than the mesh aperture of a 28-mesh sieve. The weight of the coating layers accounts for 8-20% of the total weight of the tilmicosin enteric-coated pellets. The invention further relates to a preparation method of the tilmicosin enteric-coated pellets. The tilmicosin enteric-coated pellets can cover the bitter taste of the tilmicosin, the acid stability of the preparation is ensured, and the biological utilization degree is remarkably improved.

The invention discloses a pharmaceutical composition for treating diseases including epidemic type B encephalitis and hepatic coma, which has the advantages of wherein the bolus has the advantages of high biological availability, quick-speed medicine release, quick-speed effect, less toxic and side effects, higher medicinal content, smaller amount of administration, accurate administration dosage, easy administration, low price, and facilitated carrying. The preparation is prepared through the conventional injection extracting processes.

The invention discloses to a drug compound for treating diabetes and particularly relates to a drug compound oral pharmaceutical formulation adopting pioglitazone as the ingredient. The drug compound aims to supplement the deficiency of the prior oral pharmaceutical formulation used for treating Type-2 Diabetes and provide a drug compound oral pharmaceutical formulation, sustained-release pioglitazone dropping pill which has high bioavailability, controllable release time, long-acting effect, low frequency of drug taking, steady plasma concentration, low cost and absence of contamination during the production. The sustained-release pioglitazone dropping pill adopts pioglitazone as the chemical ingredient and is prepared jointly with the medicinal carriers of hydrophilic frame ingredients and hydrophobic frame ingredients used as the stroma.